Examiner: HAGHIGHATIAN, MINA

Tech Center 1600 • Art Units: 1615 1616 1626

This examiner grants 46% of resolved cases

Analysis

Mina Haghighatian has a caseload of 881 resolved cases in Art Unit 1615. Within Tech Center 1600, her allowance rate is 46.1 percent. This indicates that a minority of the applications she reviews result in a patent grant, suggesting a rigorous examination process. Practitioners should be prepared for a thorough review of their claims.

The data reveals an interview lift of 39.3 percent. This is a significant metric for this examiner, as it suggests that interviews are effective at overcoming rejections. The median days to allowance is 1185, which is a period for prosecution. However, the 39.3 percent lift provides a path for improving the 46.1 percent base allowance rate. Given the 1185 median days to allowance and the impact of verbal communication, an early and well-prepared interview is a strategy for any applicant assigned to this examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

46.1%

Allow Rate

-13.9% vs TC avg

930

Total Applications

+39.3%

Interview Lift

1185

Avg Prosecution Days

Based on 881 resolved cases, 2023–2026

Rejection Statute Breakdown

1.6%

§101 Eligibility

8.7%

§102 Novelty

39.5%

§103 Obviousness

24.9%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
18492232	Cisplatin particles and uses thereof	Non-Final OA	CRITITECH, INC.
18721774	USE OF BISMUTH OXYCARBONATE PARTICLES FOR FILTERING ULTRAVIOLET RADIATION	Non-Final OA	L'OREAL
17772187	DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE	Non-Final OA	AstraZeneca AB
18590826	COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY	Non-Final OA	AstraZeneca Pharmaceuticals LP
17983915	DRY POWDER INHALER	Non-Final OA	MannKind Corporation
17158997	DRY POWDER INHALER	Final Rejection	MannKind Corporation
18552838	MEANS AND METHOD FOR CYTOSOLIC DELIVERY	Final Rejection	Universiteit Gent
17262421	Dry Powder Formulations for Messenger RNA	Non-Final OA	Translate Bio, Inc.
18847134	ENCAPSULATED PHEROMONE FORMULATIONS RESISTANT TO LIGHT RADIATION	Non-Final OA	MELCHIOR MATERIAL AND LIFE SCIENCE FRANCE
18561351	Inhalable Pharmaceutical Formulations	Final Rejection	Pinata Holdings Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy